Amgen Inc. (NASDAQ:AMGN) Shares Bought by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,087 shares of the medical research company’s stock after purchasing an additional 205 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Amgen were worth $3,672,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Swedbank AB grew its holdings in shares of Amgen by 1.1% in the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock worth $173,639,000 after acquiring an additional 5,751 shares during the last quarter. Graypoint LLC boosted its position in shares of Amgen by 3.0% in the 3rd quarter. Graypoint LLC now owns 5,164 shares of the medical research company’s stock valued at $1,664,000 after purchasing an additional 148 shares during the period. Cozad Asset Management Inc. increased its stake in Amgen by 3.7% in the 3rd quarter. Cozad Asset Management Inc. now owns 1,695 shares of the medical research company’s stock worth $546,000 after purchasing an additional 60 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Amgen by 6.0% during the 3rd quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company’s stock worth $204,659,000 after buying an additional 35,785 shares during the period. Finally, Western Pacific Wealth Management LP lifted its stake in Amgen by 245.2% during the third quarter. Western Pacific Wealth Management LP now owns 535 shares of the medical research company’s stock valued at $172,000 after buying an additional 380 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the transaction, the executive vice president now owns 36,922 shares in the company, valued at $11,240,533.68. The trade was a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is owned by insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $324.86 on Friday. The stock has a market capitalization of $174.52 billion, a P/E ratio of 43.03, a P/E/G ratio of 2.63 and a beta of 0.56. The business has a 50-day moving average of $286.14 and a two-hundred day moving average of $299.89. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 2.93%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio is currently 126.09%.

Analyst Upgrades and Downgrades

AMGN has been the topic of several analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Truist Financial lowered their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research report on Wednesday, January 8th. Wolfe Research began coverage on Amgen in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Redburn Partners lowered their price target on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Finally, UBS Group reissued a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $314.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.